MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
royalty bond and...
$144,493K
Proceeds from issuance of
common stock under...
$1,048K
Proceeds from exercise of
stock options
$318K
Net cash provided by
financing activities
$116,771K
Canceled cashflow
$29,088K
Net increase
(decrease) in cash and cash...
-$23,060K
Canceled cashflow
$116,771K
Stock-based compensation
expense
$34,563K
Deferred revenue
$29,280K
Depreciation and
amortization
$15,615K
Non-cash interest
expense
$12,901K
Operating lease
right-of-use assets
-$6,653K
Other current assets
-$658K
Other non-cash
adjustments
-$597K
Accrued expenses and
other current...
$229K
Maturities of marketable
debt securities
$319,114K
Sales of equity
securities
$62K
Repayments under royalty
monetization liabilities,...
$28,098K
Taxes paid related to
net settlement of...
$633K
Expenses related to
at-the-market offering...
$357K
Net cash used in
operating activities
-$123,963K
Canceled cashflow
$100,496K
Net cash provided by
(used in) investing...
-$15,868K
Canceled cashflow
$319,176K
Net loss
-$193,878K
Operating lease
liabilities
-$8,625K
Accounts receivable
$7,661K
Net accretion of
discounts on marketable...
$5,479K
Other liabilities
-$2,997K
Prepaid expenses
$2,860K
Accounts payable
-$2,284K
Other assets
$613K
Net realized gain on
investments
$62K
Purchases of marketable
debt securities
$332,630K
Purchases of property and
equipment
$2,414K
Back
Back
Cash Flow
source: myfinsight.com
REGENXBIO Inc. (RGNX)
REGENXBIO Inc. (RGNX)